Across
- 6. Autoimmune disease reviewed in a “Rheum With a View” session focusing on cutaneous manifestations at DERM 2025.
- 8. IL‑23 inhibitor with positive phase 3 results reported for psoriatic arthritis.
- 9. Biologic that Jacob Thyssen, PhD, highlighted as promising for hard‑to‑treat hand eczema.
- 11. Investigational psoriasis agent with positive phase 3 results in high‑impact areas presented at DERM 2025.
- 12. Castle Biosciences’ melanoma test that earned FDA Breakthrough Device designation for risk stratification.
- 14. (Abbreviation)Lymphoma in which pruritus severity correlated with quality of life in this week’s Journal Digest.
- 15. PDE4 inhibitor cream being studied for safety and efficacy in infants with atopic dermatitis in the INTEGUMENT-INFANT trial.
- 16. Biologic shown effective for genital and scalp psoriasis in the UnlIMMited poster at DERM 2025.
Down
- 1. TYK2 inhibitor with an FDA‑accepted sNDA for treating active psoriatic arthritis.
- 2. (Abbreviation) “Forever chemicals” Michelle Hure, MD, warned may pose clinical concerns in dermatology products.
- 3. BTK inhibitor demonstrating swift CSU activity score reductions at Elevate‑Derm Summer.
- 4. Aesthetic agents whose broader impact was explored using patient‑reported outcomes by Steven Dayan, MD.
- 5. Cancer type where gene expression profiling is transforming management of recurrence risk and treatment decisions.
- 7. Pan-JAK inhibitor cream newly FDA‑approved as the first approved therapy in the US for chronic hand eczema in adults.
- 10. testing (2 words) Diagnostic step Walter Liszewski, MD, highlighted for tailoring atopic dermatitis care.
- 13. (Abbreviation) Global health body whose new resolution on skin diseases aims to close care gaps worldwide.